痰热清联合利巴韦林治疗急性上呼吸道感染发热患者的疗效观察

目的:观察痰热清联合利巴韦林治疗急性上呼吸道感染发热患者的临床疗效。方法:将120例患者随机分为利巴韦林组、痰热清组、联合组各40例,分别给予利巴韦林注射液,痰热清注射液,利巴韦林注射液+痰热清注射液治疗,观察三组患者的临床疗效、体温起效时间、解热时间及痊愈时间。结果:利巴韦林与痰热清均能较好的治疗急性上呼吸道感染,两组差异无显著性意义(P0.05);利巴韦林组与联合组临床疗效比较,两组差异有显著性意义(P0.05);痰热清组与联合组临床疗效比较,两组差异有显著性意义(P0.05);痰热清组起效时间较利巴韦林组短,差异有显著性意义(P0.05);解热时间及痊愈时间较利巴韦林组短,差异有显著性意义(P0.01)。联合组起效时间、解热时间及痊愈时间均较利巴韦林组、痰热清组短,差异有显著性意义(P0.01)。结论:利巴韦林及痰热清对急性上呼吸道感染均有较好的治疗作用,痰热清对于急性上呼吸道感染患者退热作用比利巴韦林好,体温起效时间、解热时间、及痊愈时间较利巴韦林短,但两者临床疗效无明显差异。联合用药比单用利巴韦林或痰热清疗效较好,起效时间、解热时间、痊愈时间均较短。

Clinical observation on treating fever in patients with acute upper respiratory tract infection by Tanreqing plus ribavirin

Objective：To observe the clinical effects of Tanreqing plus ribavirin in treating fever in patients with acute upper respiratory tract infection.Methods：120 patients were randomly divided into the ribavirin group,Tanreqing group,and combined group,and were respectively given the ribavirin injection,Tanreqing injection,the ribavirin injection plus Tanreqing injection,the clinical efficacy,temperature onset time,antipyretic time and healing time of the three groups were observed.Results：Ribavirin and Tanreqing were able to better treat acute upper respiratory tract infection,the difference was not statistically significant （P0.05）;Compared the clinical efficacy of ribavirin group and the combined group,the difference was statistically significant （P0.05）;Compared the clinical efficacy of Tanreqing group and the combined group,the difference was statistically significant （P0.05）;The onset time of Tanreqing group was shorter than that of the ribavirin group,the difference was statistically significant （P0.05）;antipyretic time and healing time were shorter than that of the ribavirin group,There are significant differences （P0.01）.The onset time,antipyretic time and healing time of the ribavirin group were shorter than that of the ribavirin group and Tanreqing group,there are significant differences （P0.01）.Conclusion：Ribavirin and Tanreqing had a better therapeutic effect in treating acute upper respiratory tract infection,the antipyretic action of anreqing was better than that of ribavirin,body temperature onset time,antipyretic time,and recovery time were shorter than that of ribavirin,but no significant difference in both clinical efficacy.The effects of combination was better than that of single using ribavirin or Tanreqing,the onset time,antipyretic,healing time were shorter.